Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Mar;8(3):142-50.
doi: 10.1038/nrclinonc.2010.220.

Emerging molecular biomarkers--blood-based strategies to detect and monitor cancer

Samir M Hanash  1 , Christina S Baik, Olli Kallioniemi
Affiliations
Review

Emerging molecular biomarkers--blood-based strategies to detect and monitor cancer

Samir M Hanash et al. Nat Rev Clin Oncol. 2011 Mar.

Abstract

There is an urgent need for blood-based, noninvasive molecular tests to assist in the detection and diagnosis of cancers in a cost-effective manner at an early stage, when curative interventions are still possible. Additionally, blood-based diagnostics can classify tumors into distinct molecular subtypes and monitor disease relapse and response to treatment. Increasingly, biomarker strategies are becoming critical to identify a specific patient subpopulation that is likely to respond to a new therapeutic agent. The improved understanding of the underlying molecular features of common cancers and the availability of a multitude of recently developed technologies to interrogate the genome, transcriptome, proteome and metabolome of tumors and biological fluids have made it possible to develop clinically applicable and cost-effective tests for many common cancers. Overall, the paradigm shift towards personalized and individualized medicine relies heavily on the increased use of diagnostic biomarkers and classifiers to improve diagnosis, management and treatment. International collaborations, involving both the private and public sector will be required to facilitate the development of clinical applications of biomarkers, using rigorous standardized assays. Here, we review the recent technological and scientific advances in this field.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Br J Cancer. 2001 Jan 5;84(1):25-32 - PubMed
    1. J Clin Oncol. 2009 Dec 10;27(35):6041-51 - PubMed
    1. Br J Cancer. 2007 Sep 17;97(6):778-84 - PubMed
    1. Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9824-9 - PubMed
    1. Clin Cancer Res. 2005 Feb 1;11(3):1219-25 - PubMed

Substances

LinkOut - more resources